Inactive Instrument

Analyst Reco. Cellectar Biosciences Inc Nasdaq

Equities

Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	Mar. 28	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	Mar. 28	MT
Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating	Jan. 09	MT
Oppenheimer Cuts Cellectar Biosciences Price Target to $8 From $10, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $10 From $11, Maintains Outperform Rating	23-05-05	MT
HC Wainwright Adjusts Price Target on Cellectar Biosciences to $4 From $30, Maintains Buy Rating	22-11-04	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating	22-11-04	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $47 From $5.50, Maintains Outperform Rating	22-08-08	MT
Maxim Group Adjusts Cellectar Biosciences Price Target to $2 From $3, Maintains Buy Rating	22-02-02	MT
CELLECTAR BIOSCIENCES : Oppenheimer Adjusts Cellectar Biosciences' Price Target to $5.50 From $5, Maintains Outperform Rating	20-12-28	MT
Cellectar Biosciences, Inc. Reports Positive Top-Line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of Clr 131	19-02-25	CI

No results for this search